An Italian cohort study using GLP-1 RA and SGLT2i did not find any difference between the two groups with regard to HF-related hospitalization rates; however, other studies have shown favorably lower risk of congestive heart failure and cardiovascular events associated with SGLT2i use. The gene discussed is GLP1R; the disease is congestive heart failure.